CBD for bladder control after spinal cord injury
Official title: Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury
Run by University of Wisconsin, Madison · NCT06840899 · Data updated 2026-11-12
This test gives adults with recent supra‑sacral spinal cord injury purified CBD (Epidiolex) twice daily for 90 days to see if it reduces urinary incontinence and other bladder symptoms.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | February 13, 2026 |
| Main results expected | May 2028 |
| Study ends | May 2028 |
| Registry record updated | September 16, 2026 |
| Trial ID | NCT06840899 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with supra‑sacral spinal cord injury who have neurogenic lower urinary tract dysfunction with ≥2 incontinence episodes per day and can attend in-person visits at the University of Wisconsin–Madison are ideal candidates.
✕Probably not a fit
Patients with recent intravesical Botox, those on high-dose anticholinergics, ongoing non-study cannabis use, or significant mood/thought disorders were excluded and may not be helped by this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 2 pilot feasibility trial gives adult participants with supra‑sacral spinal cord injury purified cannabidiol (Epidiolex) 100 mg twice daily for 90 days to target neurogenic lower urinary tract dysfunction after resolution of spinal shock. Eligible participants must have at least two urinary incontinence episodes per day and meet inclusion/exclusion criteria; key exclusions include recent intravesical Botox, high-dose anticholinergic use, active non-study cannabis use, and certain mood/thought disorders. Study measures include changes in incontinence frequency and other urinary symptoms, feasibility outcomes such as recruitment and adherence, and safety/tolerability monitoring. All dosing and follow-up occur at the University of Wisconsin–Madison with urine drug screening and standardized questionnaires.
Why it matters
Potential benefit: If successful, CBD could reduce daily incontinence episodes and improve bladder-related quality of life after spinal cord injury.
How similar studies have gone: Use of purified CBD specifically for neurogenic bladder in humans is largely novel, with limited clinical data and mostly preclinical or anecdotal reports.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years of age * History of supra-sacral spinal cord injury of any mechanism * Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock) * Willingness to participate in drug intervention trial * English-speaking (able to provide consent and complete questionnaires) Exclusion Criteria: * History of intravesical Botox * Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms * Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported * Thought or mood disorder aside from depression
Where it's running
-
University of Wisconsin - Madison
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Javi Santiago — University of Wisconsin, Madison
- Study coordinator: Maria Flory
- Email: flory@ortho.wisc.edu
- Phone: 608-262-8652
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exploring the link between menstrual cycles and urinary incontinence in women with spinal cord injuries
This study looks at how changes in hormones during the menstrual cycle might affect bladder control in women with spinal cord injuries to see if it can help improve treatment options.
-
Implanted Brain-Computer Interface to Help People with Severe Arm Impairment
We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.
-
tSCS with rehabilitation for improving movement after spinal cord injury
This study tests whether adding rehabilitation training to transcutaneous spinal cord stimulation helps paraplegic patients regain voluntary movement after spinal cord injury.
-
Informational Needs of Caregivers of Patients in Neuro Rehab: Validating the QBI-R/V
This study tests a caregiver questionnaire (QBI-R and QBI-V) to see how well it measures caregivers’ informational needs during neuromotor rehabilitation.
-
Biomechanical and Perceived Effort in Manual Wheelchair Propulsion
This study tests whether combining objective shoulder loading data with how hard people feel they’re working can reveal how difficult manual wheelchair propulsion is for users with spinal cord injury.
-
Shockwave therapy added to toxin injections to help spasticity after spinal cord injury
Aims to see if focused shockwave therapy plus Botox injections reduce spasticity better than Botox alone in adults with spinal cord injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.